219 related articles for article (PubMed ID: 29914087)
21. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
[TBL] [Abstract][Full Text] [Related]
22. [Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
Scherpereel A; Grigoriu BD; Astoul P
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S183-90. PubMed ID: 18971844
[TBL] [Abstract][Full Text] [Related]
23. [New diagnostic markers for malignant pleural mesothelioma].
Grigoriu BD; Grégoire M; Chahine B; Scherpereel A
Bull Cancer; 2008 Feb; 95(2):177-84. PubMed ID: 18304902
[TBL] [Abstract][Full Text] [Related]
24. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
[TBL] [Abstract][Full Text] [Related]
25. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
26. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
27. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
28. [Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
Desoubeaux N; Bouvier V; Gervais R; Galateau-Salle F; Thibon P; Leplumey T; Herbert C; Lecherbonnier Y; Daviet JP; Letourneux M
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):523-9. PubMed ID: 11845101
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
30. Current status of screening for malignant pleural mesothelioma.
Pass HI; Carbone M
Semin Thorac Cardiovasc Surg; 2009; 21(2):97-104. PubMed ID: 19822280
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
Kim K; Ko Y; Oh H; Ha M; Kang J; Kwon EJ; Kang JW; Kim Y; Heo HJ; Kim G; Kim JW; Kim YH
J Toxicol Environ Health A; 2020 Feb; 83(3):126-134. PubMed ID: 32114955
[TBL] [Abstract][Full Text] [Related]
32. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
Fasola G; Belvedere O; Aita M; Zanin T; Follador A; Cassetti P; Meduri S; De Pangher V; Pignata G; Rosolen V; Barbone F; Grossi F
Oncologist; 2007 Oct; 12(10):1215-24. PubMed ID: 17962615
[TBL] [Abstract][Full Text] [Related]
33. Advances in the biology of malignant pleural mesothelioma.
Zucali PA; Ceresoli GL; De Vincenzo F; Simonelli M; Lorenzi E; Gianoncelli L; Santoro A
Cancer Treat Rev; 2011 Nov; 37(7):543-58. PubMed ID: 21288646
[TBL] [Abstract][Full Text] [Related]
34. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
35. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
Amati M; Tomasetti M; Mariotti L; Tarquini LM; Valentino M; Santarelli L
Mutat Res; 2008; 655(1-2):52-8. PubMed ID: 18638565
[TBL] [Abstract][Full Text] [Related]
36. Mesothelin-family proteins and diagnosis of mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441
[TBL] [Abstract][Full Text] [Related]
37. [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Ciuccarelli M; Valentino M; Governa M; Santarelli L
G Ital Med Lav Ergon; 2007; 29(3 Suppl):335-8. PubMed ID: 18409713
[TBL] [Abstract][Full Text] [Related]
38. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
39. Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.
Creaney J; Dick IM; Musk AW; Olsen NJ; Robinson BW
Biomarkers; 2016 Sep; 21(6):551-61. PubMed ID: 27009350
[TBL] [Abstract][Full Text] [Related]
40. Asbestos-related disease: screening and diagnosis.
Rodríguez Portal JA
Adv Clin Chem; 2012; 57():163-85. PubMed ID: 22870590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
